logo
GLP-1 Agonists Reduce Recurrent Atrial Fibrillation

GLP-1 Agonists Reduce Recurrent Atrial Fibrillation

Medscape16-05-2025

SAN DIEGO — Patients with obesity and diabetes are at a substantially reduced risk of having a recurrence of atrial fibrillation (AF) after ablation if they are taking a glucagon-like peptide 1 (GLP-1) receptor agonist vs another diabetes drug, according to an analysis of matched cohorts with 3 years of follow-up.
The study was retrospective, but it included more than 2500 patients taking a GLP-1 or one of the two comparators, reported Varun Sundaram, MD, PhD, section chief, Advanced Heart Failure, Louis Stokes Cleveland Veterans Affairs (VA) Medical Center, Cleveland.
After a median of 3.1 years of follow-up, the odds ratio (OR) of the primary composite outcome of time to first AF hospitalization, an AF-related procedure, or all-cause mortality was reduced by 13% (OR, 0.87; P = .03) compared with treatment with a dipeptidyl peptidase 4 (DPP-4) inhibitor or sulfonylurea.
Weight Loss Might Not Explain Effect
While weight loss on the GLP-1 did occur, Sundaram speculates that it did not fully explain the benefit of the drug, as it was only modestly greater than in the control arms (14.1% vs 10.9%). He instead believes GLP-1s have 'pleiotropic' effects, resulting in a favorable impact on the metabolic abnormalities that provide a substrate for AF recurrence.
An antidiabetic drug with a favorable impact on the long-term risk for AF recurrence is an important unmet need, according to Sundaram. While ablation offers high rates of acute AF control, he pointed to the fact that one third of patients have a recurrence within 1 year and that rates continue to rise with longer follow-ups.
'We believe this is likely related to progressive atrial substrate remodeling,' said Sundaram, who said this study supports the ability of GLP-1s to reduce the residual risk for AF recurrence after a primary ablation.
In this trial, called TRANSFORM-AF, which was a late-breaking clinical trial presented at Heart Rhythm 2025, patients with type 2 diabetes and a body mass index (BMI) > 30 who were starting a new prescription of a GLP-1, DPP-4 inhibitor, or sulfonylurea were drawn from a pool of more than 70,000 patients in the VA system.
After propensity matching on the basis of 31 covariates, 1226 patients starting a GLP-1 were compared with 1284 of those taking either a DPP-4 inhibitor or sulfonylurea. The standardized between-group difference for any one of the covariates was less than 10%.
In a secondary analysis that assessed repeating AF events with mortality as a competing risk, the risk reduction of AF recurrence over the course of follow-up was 15% (OR, 0.85), which suggested a trend (95% CI, 0.61-1.03).
The TRANSFORM-AF study was limited to patients with AF and diabetes only because this is the population in the VA system taking a GLP-1. Sundaram said it is unknown if a similar reduction in recurrence would be observed in patients without diabetes with or without obesity taking a GLP-1.
The major limitation of this study was that it was not randomized, Sundaram acknowledged. Despite propensity matching, he cautioned that the risk for residual confounding cannot be excluded.
Randomized Trial Needed
A randomized trial is needed to confirm these findings, but Sundaram said such a trial will be 'challenging' for a number of reasons. In patients with obesity and diabetes, a study design that includes randomizing patients to drugs other than GLP-1 might impair recruitment. The long-term follow-up required to accrue sufficient events might also make the study cost unattractive.
The association between GLP-1 and a reduced risk for AF recurrence in TRANSFORM-AF supported a hypothesis based on experimental studies. In a 2023 editorial accompanying a published study showing a reduction in AF in an animal model of diabetes, the authors of the editorial cited other effects — such as improvement in left ventricular function that they saw as support for effects beyond weight loss and a basis for conducting clinical trials.
The level of interest in the concept modifying the substrate of AF recurrence is 'high,' according to Sanjeev Saksena, MD, an electrophysiologist and a clinical professor of medicine at the Robert Wood Johnson Medical School, Rutgers University, New Brunswick, New Jersey. He said this study is an early step in exploring the hypothesis.
Saksena considers supportive evidence from a 'robust pilot' study essential to move toward a pivotal trial. He said that the data from this study, although provocative, are insufficient for projecting benefit.
On the basis of this study alone, 'there are several reasons to question the impact on AF,' Saksena said. For one, there was a large proportion of patients with obesity, diabetes, and AF who were excluded from the analysis for various reasons. For another, AF was not measured quantitatively. He also pointed to potential problems with the matching technique to optimize two comparable groups.
As the Heart Rhythm Society–invited discussant on this study, Saksena called for a randomized trial to prove the hypothesis. He did not agree that such a controlled trial would be impossible, noting that that GLP-1 drugs such as semaglutide are not the first-line treatment for obesity, AF, or diabetes, and that more evidence of a favorable benefit-risk ratio is needed.
He pointed out that TRANSFORM-AF had many strengths. For one, the evidence of even greater benefit in those with the highest baseline BMI was reassuring. He also agreed that that new options for preventing AF recurrence are certainly needed. Saksena said he looks forward to further evidence that the evidence of benefit can be confirmed, providing a new option for clinical practice.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Kennedy names 8 vaccine committee replacements, including COVID shot critic
Kennedy names 8 vaccine committee replacements, including COVID shot critic

Associated Press

time24 minutes ago

  • Associated Press

Kennedy names 8 vaccine committee replacements, including COVID shot critic

NEW YORK (AP) — U.S. Health Secretary Robert F. Kennedy Jr. on Wednesday named eight new vaccine policy advisers to replace the panel that he abruptly dismissed earlier this week. They include a scientist who researched mRNA vaccine technology and transformed into a conservative darling for his criticisms of COVID-19 vaccines, and a leading critic of pandemic-era lockdowns. Kennedy's decision to 'retire' the previous 17-member panel was widely decried by doctors' groups and public health organizations, who feared the advisers would be replaced by a group aligned with Kennedy's desire to reassess — and possibly end — longstanding vaccination recommendations. The new appointees to the Advisory Committee on Immunization Practices include Dr. Robert Malone, the former mRNA researcher who emerged as a close adviser to Kennedy during the measles outbreak. Malone, who runs a wellness institute and a popular blog, rose to popularity during the COVID-19 pandemic as he relayed conspiracy theories around the outbreak and the vaccines that followed. He has appeared on podcasts and other conservative news outlets where he's promoted unproven and alternative treatments for measles and COVID-19. He has claimed that millions of Americans were hypnotized into taking the COVID-19 shots. He's even suggested that those vaccines cause a form of AIDS. He's downplayed deaths related to one of the largest measles outbreaks in the U.S. in years. Other appointees include Dr. Martin Kulldorff, a biostatistician and epidemiologist who was a co-author of the Great Barrington Declaration, an October 2020 letter maintaining that pandemic shutdowns were causing irreparable harm. Dr. Cody Meissner, a former ACIP member, also was named. Kennedy made the announcement in a social media post on Wednesday. The committee, created in 1964, makes recommendations to the director of the Centers for Disease Control and Prevention. CDC directors almost always approve those recommendations on how Food and Drug Administration-cleared vaccines should be used. The CDC's final recommendations are widely heeded by doctors and determine the scope of vaccination programs. ___ Associated Press reporter Amanda Seitz contributed to this report. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.

Laika HIres SUSPIRIA Writer to Script Travis Knight's Surreal Stop-Motion Adaptation of PIRANESI — GeekTyrant
Laika HIres SUSPIRIA Writer to Script Travis Knight's Surreal Stop-Motion Adaptation of PIRANESI — GeekTyrant

Geek Tyrant

time29 minutes ago

  • Geek Tyrant

Laika HIres SUSPIRIA Writer to Script Travis Knight's Surreal Stop-Motion Adaptation of PIRANESI — GeekTyrant

Laika's adaptation of Susanna Clarke's mind-bending fantasy novel Piranesi just took a major step forward with the hiring of acclaimed screenwriter Dave Kajganich to handle the script. Kajganich, known for his work on Suspiria , Bones and All , and AMC's The Terror , is currently collaborating with some of the most respected directors in the industry, including Barry Jenkins, Ridley Scott, and Edward Berger. Now, he'll bring his talents and skills to Laika's ambitious stop-motion take on Clarke's beloved novel. 'Piranesi changed my soul and is one of the books in all the world, of any era, I most cherish,' Kajganich said in a statement. 'Having Travis' and Susanna's trust in adapting it is something I take as an honor of the highest order. They are two of the loveliest, smartest, and most humane people you can imagine, so all of this is an actual dream coming true for me.' First announced in June 2024, Piranesi will be directed by Laika President & CEO Travis Knight, who previously helmed the Oscar-nominated Kubo and the Two Strings and the upcoming Wildwood . The project marks a return to the studio's roots in stop-motion storytelling, even as they continue branching out into live-action. The story for Piranesi is set in a dreamlike alternative reality, and it follows Piranesi, 'whose house is no ordinary building: its rooms are infinite, its corridors endless, its walls are lined with thousands upon thousands of statues, each one different from all the others. 'Within the labyrinth of halls, an ocean is imprisoned; waves thunder up staircases, rooms are flooded in an instant. But Piranesi is not afraid; he understands the tides as he understands the pattern of the labyrinth itself. He lives to explore the house.' There is one other person in the house, 'a man called The Other, who visits Piranesi twice a week and asks for help with research into A Great and Secret Knowledge. 'But as Piranesi explores, evidence emerges of another person, and a terrible truth begins to unravel, revealing a world beyond the one Piranesi has always known.' Since its release, Clarke's novel has become a literary phenomenon, selling over four million copies and winning the 2021 Women's Prize for Fiction. Its meditative tone, philosophical depth, and strange beauty seem tailor-made for Laika's visual storytelling. Knight previously shared in a statement: ' Piranesi is a treasure, and very dear to me. As a filmmaker, I can scarcely imagine a more joyful experience than wandering through the worlds Susanna dreamed into being. 'She's one of my all-time favorite authors, and with Piranesi , Susanna has created a beautiful, devastating and ultimately life-affirming work of art. I'm humbled that she chose LAIKA as her home.' Kajganich is also working on Brad Pitt's The Riders , he's also scripting Be My Baby , a Ronnie Spector biopic for A24, with Zendaya set to star and Barry Jenkins directing. While Laika continues to push further into live-action—with projects like Atmosphere from Anna Boden and Ryan Fleck, and Crumble from Brian Duffield and producers Phil Lord and Chris Miller, the studio hasn't lost sight of what made them a fan favorite in the first place: bold, stylized stop-motion animation that tell stories with emotional weight. Source: Deadline

Taletrectinib Approved for NSCLC
Taletrectinib Approved for NSCLC

Medscape

timean hour ago

  • Medscape

Taletrectinib Approved for NSCLC

The FDA has approved taletrectinib (Ibtrozi, Nuvation Bio) for locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) in first- and later-line settings, regardless of prior ROS1 tyrosine kinase inhibitor (TKI) exposure. Taletrectinib is considered a next-generation ROS1 TKI to distinguish it from two first-generation products already on the US market: crizotinib and entrectinib. A third ROS1 TKI approved in 2023, repotrectinib, is also a next-generation medicine. Like repotrectinib, FDA granted taletrectinib a breakthrough therapy designation. Compared with crizotinib and entrectinib, Nuvation Bio data suggests taletrectinib has greater brain penetration, lower incidence of neurologic adverse events, less likelihood of resistance, and other benefits, plus a possible safety and efficacy edge over next-generation rival repotrectinib. 'Taletrectinib will likely become the preferred treatment option for advanced ROS1+ NSCLC,' commented Thomas E. Stinchcombe, MD, an associate editor at the Journal of Clinical Oncology , in the 'Context' section of his journal's publication of a pooled analysis of Nuvation Bio's two approval studies, TRUST-I and TRUST-II, in April. Taletrectinib was originally developed in China and was approved there in Jan 2025 for the same indication granted by FDA. The company plans a US launch in mid-2025, they stated in a press release. About 2% of NSCLC patients have ROS1-positive disease, and about a third of them present with brain metastases. ROS1-positive patients have an oncogenic rearrangement in the ROS1 gene, which leads to an abnormal ROS1 fusion protein that drives cancer growth. ROS1 TKIs block the protein's activity. The drug's approval was based on results of TRUST-I and TRUST-II, phase 2, single-arm, open label studies in ROS1-positive NSCLC patients treated with oral taletrectinib 600 mg once daily until progression, unacceptable toxicity, death, or consent withdrawal. Of the 273 subjects in the pooled analysis, 93.8% had stage IV disease, 33.7% had brain metastases, and 27.1% had received chemotherapy. TRUST-I included Chinese subjects who were either new to TKIs or who had received crizotinib. TRUST-II included patients from North America, Europe, and Asia who were TKI-naive or who had been treated with crizotinib or entrectinib. The efficacy population included 157 patients (103 in TRUST-I; 54 in TRUST-II) who were naive to treatment with a ROS1 TKI and 113 patients (66 in TRUST-I; 47 in TRUST-II) who had received one prior ROS1 TKI. Patients may have received prior chemotherapy for advanced disease. For treatment-naive patients, the overall response rate (ORR) was 90% in TRUST-I and 85% in TRUST-II, with 72% and 63% of responders having a duration of response (DOR) of at least a year, respectively. For TKI-pretreated patients, ORR was 52% in TRUST-I and 62% in TRUST-II, with 74% and 83% of responders having a DOR of at least 6 months, respectively. Among 13 patients with a G2032R mutation, which triggers resistance to first generation ROS1 TKIs, eight (61.5%) had a response to taletrectinib. In a safety analysis with 352 patients, the most frequent treatment-emergent adverse events with taletrectinib were gastrointestinal problems (88%) and elevated aspartate aminotransferase (72%) and alanine aminotransferase (68%). Neurologic adverse events included dizziness (21%) and dysgeusia (15%). Overall, 33% of patients had grade 3 or higher treatment-related adverse events. Treatment-emergent adverse events led to discontinuation in 7% of patients. There were three treatment-related deaths due to abnormal hepatic function, liver failure, and pneumonia. Prescribing information for taletrectinib includes warnings and precautions for hepatotoxicity, interstitial lung disease/pneumonitis, QTc interval prolongation, hyperuricemia, myalgia with creatine phosphokinase elevation, skeletal fractures, and embryo-fetal toxicity. The recommended taletrectinib dose is 600 mg orally once daily on an empty stomach until disease progression or unacceptable toxicity. Taletrectinib pricing was not available, but fourteen 160 mg capsules of rival repotrectinib — the initial 2-week supply with daily dosages doubling afterwards — is $7,666.97, according to

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store